Results 91 to 100 of about 7,902 (191)

Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension

open access: yesVascular Health and Risk Management, 2008
Luis M RuilopeUnidad de Hipertensión, Hospital 12 de Octubre, Madrid, SpainAbstract: Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year, and identification and ...
Luis M Ruilope
doaj  

Severe Hepatitis Complicating Olmesartan Enteropathy: A Case Report

open access: yesCase Reports in Gastroenterology
Introduction: Olmesartan, an angiotensin II receptor antagonist, is associated with an uncommon complication of enteropathy that presents insidiously, usually months to years after initial commencement of anti-hypertensive therapy which can be dose ...
Ruyi Tan   +5 more
doaj   +1 more source

Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis

open access: yes, 2015
Philipp Sievers,1 Lorenz Uhlmann,2 Sevil Korkmaz-Icöz,3 Christian Fastner,1 Florian Bea,1 Erwin Blessing,1 Hugo A Katus,1 Michael R Preusch11Department of Internal Medicine III, 2Institute of Medical Biometry and Informatics, 3Department of ...
Katus HA   +7 more
core  

Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil

open access: yes, 2004
BACKGROUND: The orally active, nonpeptide antagonists of the angiotensin II subtype 1 (AT1) receptor represent a recent class of antihypertensive drugs that selectively block the renin-angiotensin system. Olmesartan medoxomil is the newest member of this
Koike H   +5 more
core   +1 more source

Angioprotection role in arterial hypertension treatment: focus on olmesartan

open access: yesКардиоваскулярная терапия и профилактика, 2012
The paper discusses the role of organoprotection in arterial hypertension treatment. The results of international studies on effectiveness of olmesartan, a modern angiotensin II receptor antagonist, are presented. The available evidence confirms not only
D. V. Nebieridze   +3 more
doaj   +1 more source

Systematic review: Sprue-like enteropathy associated with olmesartan

open access: yes, 2014
The onset of a sprue-like enteropathy in association with olmesartan therapy has been recently ...
Montalto, Massimo   +3 more
core   +2 more sources

Severe Spruelike Enteropathy Associated With Olmesartan

open access: yes, 2012
Objective: To report the response to discontinuation of olmesartan, an angiotensin II receptor antagonist commonly prescribed for treatment of hypertension, in patients with unexplained severe spruelike enteropathy.Patients and Methods: All 22 patients ...
Mangan, Thomas F.,   +13 more
core   +1 more source

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION

open access: yesРоссийский кардиологический журнал, 2012
The pharmacoeconomic analysis compared the strategies of arterial hypertension (AH) management using different angiotensin II receptor blockers (ARB). The first stage of the analysis included the cost-effectiveness modelling in patients with moderate AH ...
S. G. Gorokhova, V. V. Ryazhenov
doaj  

Seronegative Intestinal Villous Atrophy: A Diagnostic Challenge

open access: yesCase Reports in Gastrointestinal Medicine, 2016
Celiac disease is the most important cause of intestinal villous atrophy. Seronegative intestinal villous atrophy, including those that are nonresponsive to a gluten-free diet, is a diagnostic challenge.
Cláudio Martins   +10 more
doaj   +1 more source

BLOOD PRESSURE-LOWERING EFFICACY OF OLMESARTAN RELATIVE TO OTHER ANGIOTENSIN II RECEPTOR ANTAGONISTS: AN OVERVIEW OF RANDOMIZED CONTROLLED STUDIES

open access: yesРоссийский кардиологический журнал, 2010
The aim of the present work was to review published studies, investigating the dose-related efficacy on blood pressure (BP) of olmesartan and of other commercially available angiotensin II type I receptor blockers (ARBs).
Faiez Zannad, Renaud Fay
doaj  

Home - About - Disclaimer - Privacy